UC San Diego researchers join national effort to better understand human immune system as part of new Allen Institute of Immunology.
The Trestles supercomputer, which was acquired more than three years ago by the Arkansas High Performance Computing Center (AHPCC) at the University of Arkansas after entering service at the San Diego Supercomputer Center in 2011, is still going strong.
David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research into cancer’s ability to overcome stress, gain drug resistance and metastasize.
Researchers find that patients with severe, refractory schizophrenia benefit from targeted cognitive therapy, improving auditory and verbal outcomes and the way they process information.
Researchers spent two years testing chemical compounds for their ability to inhibit the malaria parasite at an earlier stage in its lifecycle than most current drugs, revealing a new set of chemical starting points for the first drugs to prevent malaria instead of just treating the symptoms.
University of California San Diego School of Medicine researchers engineered sensors to detect and measure the metastatic potential of single cancer cells. Metastasis is attributed as the leading cause of death in people with cancer.
UC San Diego Medical Center in Hillcrest was named a Top Teaching Hospital by The Leapfrog Group. The award is widely acknowledged as one of the most competitive honors that a U.S. hospital can receive.
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.
Following the FDA’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.